Argent Trust Co Has $4.31 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Argent Trust Co boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 11.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,685 shares of the medical equipment provider’s stock after acquiring an additional 962 shares during the period. Argent Trust Co’s holdings in Intuitive Surgical were worth $4,308,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ridgewood Investments LLC acquired a new stake in Intuitive Surgical during the second quarter worth about $26,000. Creekmur Asset Management LLC increased its position in Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 42 shares in the last quarter. LGT Financial Advisors LLC increased its position in Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 54 shares in the last quarter. Delos Wealth Advisors LLC lifted its stake in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares during the last quarter. Finally, LRI Investments LLC acquired a new stake in Intuitive Surgical in the first quarter valued at approximately $30,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Trading Down 1.6 %

Shares of NASDAQ ISRG opened at $483.32 on Wednesday. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.18. The firm has a market capitalization of $171.43 billion, a P/E ratio of 87.24, a P/E/G ratio of 5.41 and a beta of 1.39. The firm’s 50-day moving average price is $465.50 and its 200-day moving average price is $423.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the previous year, the company posted $1.18 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. Equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Wall Street Analyst Weigh In

ISRG has been the subject of several research analyst reports. BTIG Research upped their price target on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Barclays upped their target price on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their target price for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Finally, Citigroup raised their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,120 shares of company stock valued at $25,528,753. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.